A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
Status:
Completed
Trial end date:
2018-04-03
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, dose-escalation study. Enrollment is
planned to occur at approximately 14 global sites. Approximately 24 subjects with CF.